Parkman Healthcare Partners LLC grew its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 20.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 529,877 shares of the company’s stock after buying an additional 91,132 shares during the period. […]
Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) dropped 2.9% during mid-day trading on Wednesday . The stock traded as low as $22.53 and last traded at $22.58. Approximately 221,725 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 627,652 shares. The stock had previously closed at $23.25. […]
CAMBRIDGE, Mass., June 01, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in.
Cullinan Therapeutics, Inc. announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial. As of.
Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) fell 4.5% on Tuesday . The company traded as low as $22.99 and last traded at $23.05. 266,559 shares traded hands during trading, a decline of 58% from the average session volume of 630,100 shares. The stock had previously closed at $24.13. Wall Street Analysts Forecast Growth […]